User login
Key clinical point: Palbociclib dose reduction occurs in real-world practice among patients with advanced breast cancer (BC) and has no negative clinical outcomes. It is more common in older patients, with no effect on survival.
Major finding: Overall, palbociclib dose reduction occurred in 33% of patients, with median time-to-next treatment (P < .001) and median overall survival (OS; P = .003) significantly longer in patients with vs without dose reduction. Dose reductions were more common in patients aged ≥70 years vs <70 years (P = .041), with no effect observed on median OS (P = .051).
Study details: This real-world analysis included 598 patients (median age, 64 years) with hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced BC who were treated with palbociclib combined with either fulvestrant or aromatase inhibitors.
Disclosures: This study was funded by Dutch health insurer VGZ. The authors declared no conflict of interests.
Source: Ismail RK et al. Breast. 2021 Nov 17. doi: 10.1016/j.breast.2021.11.013.
Key clinical point: Palbociclib dose reduction occurs in real-world practice among patients with advanced breast cancer (BC) and has no negative clinical outcomes. It is more common in older patients, with no effect on survival.
Major finding: Overall, palbociclib dose reduction occurred in 33% of patients, with median time-to-next treatment (P < .001) and median overall survival (OS; P = .003) significantly longer in patients with vs without dose reduction. Dose reductions were more common in patients aged ≥70 years vs <70 years (P = .041), with no effect observed on median OS (P = .051).
Study details: This real-world analysis included 598 patients (median age, 64 years) with hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced BC who were treated with palbociclib combined with either fulvestrant or aromatase inhibitors.
Disclosures: This study was funded by Dutch health insurer VGZ. The authors declared no conflict of interests.
Source: Ismail RK et al. Breast. 2021 Nov 17. doi: 10.1016/j.breast.2021.11.013.
Key clinical point: Palbociclib dose reduction occurs in real-world practice among patients with advanced breast cancer (BC) and has no negative clinical outcomes. It is more common in older patients, with no effect on survival.
Major finding: Overall, palbociclib dose reduction occurred in 33% of patients, with median time-to-next treatment (P < .001) and median overall survival (OS; P = .003) significantly longer in patients with vs without dose reduction. Dose reductions were more common in patients aged ≥70 years vs <70 years (P = .041), with no effect observed on median OS (P = .051).
Study details: This real-world analysis included 598 patients (median age, 64 years) with hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced BC who were treated with palbociclib combined with either fulvestrant or aromatase inhibitors.
Disclosures: This study was funded by Dutch health insurer VGZ. The authors declared no conflict of interests.
Source: Ismail RK et al. Breast. 2021 Nov 17. doi: 10.1016/j.breast.2021.11.013.